Won Tae Chung

Won Tae Chung

Auto-generated profile, based on publicly available information

Won Tae Chung

Division of Rheumatology, Department of Internal Medicine Dong‐A University Hospital Busan Korea

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CSCeli Sun
Celi Sun
JMJulio E Molineros
Julio E Molineros
LLLoren L Looger
Loren L Looger
Xu-Jie ZhouXu-Jie Zhou
Xu-Jie Zhou
KKKwangwoo Kim
Kwangwoo Kim
SNSwapan K. Nath
Swapan K. Nath
Swapan Nath, Sang-Cheol Bae and colleagues report the results of a large-scale association study of systemic lupus erythematosus in individuals of Asian ancestry. They identify several new susceptibility loci and find enrichment for signals near genes implicated in B cell and T cell function. Systemic lupus erythematosus (SLE) has a strong but incompletely understood genetic architecture. We conducted an association study with replication in 4,478 SLE cases and 12,656 controls from six East Asian cohorts to identify new SLE susceptibility loci and better localize known loci. We identified ten new loci and confirmed 20 known loci with genome-wide significance. Among the new loci, the most significant locus was GTF2IRD1-GTF2I at 7q11.23 (rs73366469, Pmeta = 3.75 × 10−117, odds ratio (OR) = 2.38), followed by DEF6, IL12B, TCF7, TERT, CD226, PCNXL3, RASGRP1, SYNGR1 and SIGLEC6. We identified the most likely functional variants at each locus by analyzing epigenetic marks and gene expression data. Ten candidate variants are known to alter gene expression in cis or in trans. Enrichment analysis highlights the importance of these loci in B cell and T cell biology. The new loci, together with previously known loci, increase the explained heritability of SLE to 24%. The new loci share functional and ontological characteristics with previously reported loci and are possible drug targets for SLE therapeutics.

25 April 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JMJulio E. Molineros
Julio E. Molineros
LLLoren L. Looger
Loren L. Looger
KKKwangwoo Kim
Kwangwoo Kim
YOYukinori Okada
Yukinori Okada
CTChikashi Terao
Chikashi Terao
SNSwapan K. Nath
Swapan K. Nath
Human leukocyte antigen (HLA) is a key genetic factor conferring risk of systemic lupus erythematosus (SLE), but precise independent localization of HLA effects is extremely challenging. As a result, the contribution of specific HLA alleles and amino-acid residues to the overall risk of SLE and to risk of specific autoantibodies are far from completely understood. Here, we dissected (a) overall SLE association signals across HLA, (b) HLA-peptide interaction, and (c) residue-autoantibody association. Classical alleles, SNPs, and amino-acid residues of eight HLA genes were imputed across 4,915 SLE cases and 13,513 controls from Eastern Asia. We performed association followed by conditional analysis across HLA, assessing both overall SLE risk and risk of autoantibody production. DR15 alleles HLA-DRB1*15:01 (P = 1.4x10-27, odds ratio (OR) = 1.57) and HLA-DQB1*06:02 (P = 7.4x10-23, OR = 1.55) formed the most significant haplotype (OR = 2.33). Conditioned protein-residue signals were stronger than allele signals and mapped predominantly to HLA-DRB1 residue 13 (P = 2.2x10-75) and its proxy position 11 (P = 1.1x10-67), followed by HLA-DRB1-37 (P = 4.5x10-24). After conditioning on HLA-DRB1, novel associations at HLA-A-70 (P = 1.4x10-8), HLA-DPB1-35 (P = 9.0x10-16), HLA-DQB1-37 (P = 2.7x10-14), and HLA-B-9 (P = 6.5x10-15) emerged. Together, these seven residues increased the proportion of explained heritability due to HLA to 2.6%. Risk residues for both overall disease and hallmark autoantibodies (i.e., nRNP: DRB1-11, P = 2.0x10-14; DRB1-13, P = 2.9x10-13; DRB1-30, P = 3.9x10-14) localized to the peptide-binding groove of HLA-DRB1. Enrichment for specific amino-acid characteristics in the peptide-binding groove correlated with overall SLE risk and with autoantibody presence. Risk residues were in primarily negatively charged side-chains, in contrast with rheumatoid arthritis. We identified novel SLE signals in HLA Class I loci (HLA-A, HLA-B), and localized primary Class II signals to five residues in HLA-DRB1, HLA-DPB1, and HLA-DQB1. These findings provide insights about the mechanisms by which the risk residues interact with each other to produce autoantibodies and are involved in SLE pathophysiology. The Human leukocyte antigen (HLA) region is a key genetic factor conferring risk of systemic lupus erythematosus (SLE). In spite of multiple SLE association signals identified in the HLA region, only amino-acid residues within HLA-DRB1 have been specifically described previously. In this study, we performed an imputation-based analysis on individuals with East Asian ancestry, and characterized SLE risk within the HLA region for all involved independent genes (HLA-DRB1, HLA-DPB1, HLA-DQB1, HLA-A, and HLA-B). Furthermore, we identified a characteristic SLE risk residue signature as well as a pattern of specific nRNP and Ro/La autoantibody residues located in the peptide-binding grooves, suggesting their key involvement in autoantibody production.

7 January 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SPSo Youn Park
So Youn Park
SLSung Won Lee
Sung Won Lee
HSHwa-Kyoung Shin
Hwa-Kyoung Shin
WCWon Tae Chung
Won Tae Chung
Won Suk LeeWon Suk Lee
Won Suk Lee
CKChi Dae Kim
Chi Dae Kim
Objective: To assess the effects of cilostazol in inhibiting proliferation and enhancing apoptosis in synovial cells from patients with rheumatoid arthritis (RA).Methods: Synovial cell proliferation was measured by MTT assay. The expression of NF‐κB, IκBα, Bcl‐2, Bax, heme oxygenase 1 (HO‐1), and Nrf2 was determined by Western blotting.Results: Cilostazol suppressed synovial cell proliferation by arresting the G2/M phases of the cell cycle, and this was reversed by KT5720, an inhibitor of protein kinase A. Cilostazol increased the number of TUNEL‐positive cells, with increased cytochrome c release and apoptosis‐inducing factor translocation as well as increased caspase 3 activation. Cilostazol (10 μM) and cobalt protoporphyrin IX (CoPP) increased HO‐1 messenger RNA and protein expression. These effects were suppressed by zinc protoporphyrin IX (ZnPP), an HO‐1 inhibitor. Cilostazol and CoPP significantly increased IκBα in the cytosol and decreased NF‐κB p65 expression in the nucleus. Increased expression of tumor necrosis factor α (TNFα), interleukin‐1β (IL‐1β), and IL‐6 induced by lipopolysaccharide was attenuated by cilostazol and CoPP, and this was reversed by ZnPP. In mice with collagen‐induced arthritis treated with cilostazol (10 and 30 mg/kg/day), paw thickness was decreased with increased apoptotic cells in the joints. In synovial cells transfected with small interfering RNA (siRNA) targeting HO‐1, cilostazol did not suppress expression of TNFα, IL‐1β, and IL‐6, in contrast to findings with negative control cells. Cilostazol‐ and CoPP‐induced HO‐1 expression was diminished in cells transfected with Nrf2 siRNA.Conclusion: Cilostazol suppressed proliferation of synovial cells from RA patients by enhancing apoptosis, and also inhibited cytokine production via mediation of cAMP‐dependent protein kinase activation–coupled Nrf2‐linked HO‐1 expression.

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SLSung Won Lee
Sung Won Lee
SLShin-Seok Lee
Shin-Seok Lee
DODong Ho Oh
Dong Ho Oh
DPDong-Jin Park
Dong-Jin Park
HKHyun-Sook Kim
Hyun-Sook Kim
SKSeong-Kyu Kim
Seong-Kyu Kim
Lee SW, et al. J Korean Med Sci. 2016 Oct;31(10):1566-1570. https://doi.org/10.3346/jkms.2016.31.10.1566

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YSYoon-Kyoung Sung
Yoon-Kyoung Sung
SCSoo-Kyung Cho
Soo-Kyung Cho
DKDam Kim
Dam Kim
BYBo Young Yoon
Bo Young Yoon
CCChan-Bum Choi
Chan-Bum Choi
TIthe KORONA Investigators
the KORONA Investigators
Sung YK, et al. J Korean Med Sci. 2016 Dec;31(12):1907-1913. https://doi.org/10.3346/jkms.2016.31.12.1907

23 December 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
Chang-Hee SuhChang-Hee Suh
Chang-Hee Suh
YLYoonhee Lee
Yoonhee Lee
SYSang‐Bae Yoo
Sang‐Bae Yoo
HQHolly Quasny
Holly Quasny
ARAldo Amador Navarro Rojas
Aldo Amador Navarro Rojas
SBSuk-Chul Bae
Suk-Chul Bae
Aim: This post hoc analysis evaluated the efficacy and safety of intravenous belimumab 10 mg/kg in the South Korean subgroup of patients with systemic lupus erythematosus (SLE) enrolled in the North East Asia (NEA) study (GSK Study BEL113750; NCT01345253).Methods: NEA was a double‐blind, placebo‐controlled, randomized Phase 3 trial. Patients with active, autoantibody‐positive SLE were randomized 2:1 to belimumab or placebo plus standard therapy administered on Days 0, 14, and 28, and then every 28 days up to Week 48. The primary efficacy endpoint in this analysis was SLE Responder Index 4 (SRI‐4) response rate at Week 52, defined as the proportion of patients achieving a ≥4‐point reduction in Safety of Estrogens in Lupus Erythematosus National Assessment‐SLE Disease Activity Index (SELENA‐SLEDAI) score, no worsening (<0.3 increase from baseline) in Physician Global Assessment, no new British Isles Lupus Assessment Group (BILAG) A domain and <2 new BILAG B domain scores.Results: Among 100 South Korean patients enrolled in NEA, 54/66 (81.8%) belimumab‐ and 24/34 (70.6%) placebo‐treated patients completed the double‐blind phase. Significantly more belimumab‐ than placebo‐treated patients achieved SRI‐4 response at Week 52 (n = 35/66, 53.0% vs. n = 8/34, 23.5%; odds ratio [OR; 95% confidence interval (CI)]: 3.67 [1.45, 9.28]; p = .0061). The proportion of patients experiencing ≥1 adverse event was similar between groups (belimumab: n = 60/66, 90.9% vs. placebo: n = 31/34, 91.2%). No new safety signals emerged in this subgroup analysis.Conclusion: Belimumab was efficacious for the treatment of SLE and well tolerated among the South Korean subgroup of patients from the NEA study.